Biotech Startups
9,920 companies tagged Biotech, with their investors and founders.
Resonant develops antibody-based therapeutics for oncology using deep cancer biology and drug discovery expertise. The company leverages world-class antibody engineering capabilities to advance oncology drug programs.
2 investors
Respira develops inhaled therapeutic products for pulmonary diseases, including a novel dry-powder inhalation device and lead product candidate RT234 for pulmonary arterial hypertension. The company focuses on creating drug-device combination products using advanced particle engineering and formulation technologies.
2 investors
First-in-class optogenetic therapy for retinal diseases; acquired by Allergan.
2 investors
Rev Genomics uses genomic selection, tissue culture, and molecular analysis to develop high-value crop cultivars for breeders and seed banks. The company creates novel plant phenotypes and provides molecular fingerprinting and breeding technology primarily for specialty crops in California.
2 investors
RevBio develops a biomimetic bone adhesive platform derived from marine biology for bone repair and regenerative applications across dental, orthopedic, and neurosurgical indications. The company is conducting first-in-human clinical trials on its regenerative bone glue technology.
2 investors
2 investors
Rgenta develops orally available small molecule therapies that target RNA to address diseases previously considered undruggable, with programs in oncology (targeting proteins such as MYB in solid tumors and hematologic cancers) and central nervous system repeat expansion disorders like Huntington's disease. It operates in the RNA-targeted drug development space.
2 investors
RheaVita manufactures scalable freeze-dryer systems for pharmaceutical and vaccine development, ranging from R&D models to GMP-compliant production units. The company serves pharmaceutical and biotech manufacturers seeking to accelerate drug development and lyophilization scaling.
2 investors
Ribbon Bio develops cell-free DNA synthesis and analysis products for research and diagnostics applications. The company operates in the biotechnology and genomics sector.
2 investors
Ribolia (ηεηη©) is a pioneer in RNAi technology and small nucleic acid drug development, with research platforms covering drug delivery, chemical modification, and multi-target drug development. The company serves patients with chronic diseases including cardiovascular, metabolic, kidney, and liver conditions through its siRNA pipeline.
2 investors
RiboNova is a biopharmaceutical company developing small molecule drugs and precision medicines targeting transfer RNA for the treatment of mitochondrial disease. The company operates a proprietary drug discovery platform with a Phase-2 ready candidate in its pipeline.
2 investors
Ricovr Healthcare develops point-of-care diagnostic technology for fast, on-site testing aimed at improving workplace safety and healthcare. The company builds medical devices in the diagnostics space.
2 investors
Rigel is a biopharmaceutical company that develops and markets therapies including olutasidenib, pralsetinib, and fostamatinib for conditions such as acute myeloid leukemia and chronic immune thrombocytopenia. This page invites investigator-sponsored research proposals, offering study drug and/or monetary grants for independent studies aligned with Rigel's therapeutic areas.
2 investors
Rise Therapeutics develops oral immunotherapies, called Oral Immune BioModulators, using a synthetic biology-based drug design approach to treat autoimmune diseases and cancer. The company combines immunology research with in-house clinical GMP manufacturing and regulatory expertise to advance its pipeline through clinical validation.
2 investors
RNA Diagnostics is a clinical-stage molecular diagnostics company developing a predictive biomarker platform to guide personalized cancer therapy management. The company's technology helps physicians optimize treatment decisions for cancer patients, particularly in breast cancer, to improve outcomes and reduce healthcare costs.
2 investors
Instem provides SaaS platforms for life sciences research organizations, covering in silico analytics, study management, regulatory submission support, and clinical trial analytics to accelerate drug and therapy development.
2 investors
Roivant develops pharmaceutical medicines and medical technologies through a subsidiary model called "Vants," focused on accelerating the development and commercialization of treatments for dermatology and other therapeutic areas. The company operates as a biopharmaceutical holding with multiple focused companies advancing drug candidates through clinical trials and commercial launch.
2 investors
Romix Bio develops technology to generate deeper insights into disease biology and therapeutic activity. The page provides minimal detail about its specific products or offerings.
2 investors
Rona Therapeutics develops siRNA-based therapeutics using its GAIA platform to target metabolic and cardiovascular conditions including hypertriglyceridemia, obesity, ASCVD, and MASH. Its pipeline includes APOC3, INHBE, PCSK9-Lp(a), and angiotensinogen-targeting candidates for patients with cardiovascular and metabolic diseases.
2 investors
RQ Bio discovers and develops long-acting monoclonal antibodies (LAAbs) targeting seasonal influenza to provide protection against severe viral disease. It focuses on immunocompromised populations such as newborns, the elderly, and patients with weakened immunity who may not respond well to seasonal vaccines.
2 investors
RyCarma Therapeutics develops a novel drug class called Rycals to treat orphan skeletal muscle and cardiac diseases, building on foundational cardiovascular research and drug-delivery technologies.
2 investors
Ryme Medical develops a catheter-based therapy to treat chronic obstructive pulmonary disease (COPD) by reducing airway inflammation and improving patient outcomes. The company targets patients with COPD who are inadequately managed by existing medications and pulmonary rehabilitation.
2 investors
S-Biomedic develops microbiome-based skincare products designed to restore the skin's healthy microbial balance for people with certain skin conditions. The company applies probiotic science to cosmetic skincare solutions.
2 investors
SafeHeal is a medical device manufacturer developing anastomosis protection devices for colorectal surgery. Its investigational device, Colovac, aims to protect the anastomosis after colorectal surgery and eliminate the need for diverting ostomy in patients undergoing colectomy, serving colorectal surgeons and cancer patients.
2 investors